# Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

> **NCT00960349** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 14 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Cediranib
- **DRUG:** Cisplatin
- **DRUG:** S-1
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00960349
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-01
- **Final completion:** 2011-03
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2011-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960349, "Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00960349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*